Please enable JavaScript.
Coggle requires JavaScript to display documents.
CNS biologics target landscape - Coggle Diagram
CNS biologics target landscape
Approved but not brain penetrant
TNF-α inhibitors for AD and other
Oncology therapeutics
EGFR antibody
VEGF antibody
many others
Enzyme replacement for LSDs
Approved, CNS targeted, with limited penetrance
CGRP inhibitors for migraine
CNS penetrance is not thought to be present
GLP-1 agonists for obesity / diabetes
No data on CSF levels, but assumed to be trivial
Clinical stage, active
TREM2 activating (AD)
PRGN replacement
CD20 antibody (MS)
Aβ antibodies (AB)
tau antibodies (AD)
Clinical stage, inactive/discontinued ??
Preclinical / potential targets
Opioid receptors
oligos for PD
CD20
GCase
GDNF
BACE-1
GAA